Ligand Pharmaceuticals confirms $3M investment in Dianomi Therapeutics
Category: #health  By Saif Ali Bepari  Date: 2019-02-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ligand Pharmaceuticals confirms $3M investment in Dianomi Therapeutics

Biopharmaceutical firm Dianomi Therapeutics, Inc., which is focused on the optimization of therapeutic profile of biologics for improving patient efficacy, safety, and dosing, has reportedly secured an investment of $3 million from Ligand Pharmaceuticals Incorporated.

According to the reports, the amount paid by Ligand is in exchange for a loan convertible into $1 million of equity at the next qualified financing. Primarily, Ligand will get a two or three percent tiered royalty based on the net sales level for the initial five products that would be approved using the Mineral Coated Microparticle (MCM) technology of Dianomi.

Sources familiar with the matter cited that Ligand would be providing scientific as well as technical advisory assistance for one year to Dianomi. Ligand would not incur any expenses for developing or commercializing any MCM programs. The MCM technology supposedly imitates the ability of human teeth and bones for protecting and storing biologics, and also offers greatly enhanced, sustained release delivery of active biologics.

Dianomi Therapeutics is apparently focused on improving the efficacy and delivery of small and large molecules in the treatment of various types of diseases, along with on therapies for inflammatory diseases, like pain and osteoarthritis. Initial focus of Dianomi would be on developing novel formulations of existing drugs in the pain and osteoarthritis space.

Co-Founder and Chief Executive Officer of Dianomi Therapeutics, Barry Kurokawa, has been a biotech fund manager, which includes serving at Invesco, as a senior portfolio manager for more than 25 years. Kurokawa has served as a board of director for various public and private healthcare firms and currently is a board member of Eirion Therapeutics, Inc.

Co-Founder and Chief Scientific Officer of Dianomi Therapeutics, William Murphy, Ph.D., is a professor of Biomedical Engineering at the University of Wisconsin-Madison. Dr. Murphy has co-founded several start-up companies, filed more than 50 patents, and published over 170 scientific manuscripts. The team also includes Carter Cliff, Co-Founder; Kurtis Knapp, PhD, Co-Founder; Co-Founder, Sr. Scientist, Anna Clements, PhD; and Co-Founder, Martin Ostrowski, JD, COO & GC.



About Author

Saif Ali Bepari

Email: [email protected]   

Saif Ali Bepari

Saif Ali Bepari currently works a content writer for Market Size Forecasters, Algosonline, and numerous other platforms. A Computer Science graduate who has a zest for writing over coding, he has previously dabbled into technical and creative writing. He now pens down...

Read More

More News By Saif Ali Bepari

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Saif Ali Bepari

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Saif Ali Bepari

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Saif Ali Bepari

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...